key: cord-0037032-7j8uyee2
authors: Dahmer, Mary K.; Quasney, Michael W.
title: Genetic Polymorphisms in Critical Care and Illness
date: 2008-11-15
journal: Science and Practice of Pediatric Critical Care Medicine
DOI: 10.1007/978-1-84800-921-9_16
sha: d1cf2bdb5b968c88abf0aa8b51788f0769113989
doc_id: 37032
cord_uid: 7j8uyee2

nan

Although the vast majority of nuclear DNA is identical from one person to the next, there is a small fraction of DNA sequence (∼0.1%) that varies among individuals. The variations in DNA sequence found within regions that make up genes are responsible for the genetically determined variation in our physical characteristics, our physiology, and our personality traits. Genetic variability also appears to be involved in susceptibility to some diseases, as well as therapeutic responses to treatment. Recent data have also suggested that genetic variations may affect the severity of some illnesses, thereby impacting the fi nal outcome of these illnesses. In this chapter, we explore the evidence for whether genetic variation has an impact on critical illness and response to injury. We discuss how genetic variations may infl uence susceptibility to, severity of, and outcome from critical illness and injury and how they may help to identify risk factors for complications in children in the pediatric intensive care unit (PICU).

The sequencing of the human genome has revealed that many genes are polymorphic, that is, there are small differences in DNA sequences among individuals. Polymorphic genes are genes in which variation at a specifi c site is found in greater than 1% of the general population. The sites that are variable within the genes are referred to as polymorphic sites. The polymorphisms in DNA sequences may exist in several forms, with the most frequent form being a single nucleotide polymorphism (SNP) caused by a base number of different techniques that have been used for genotyping. Until recently most of these techniques were labor intensive, required experienced personnel, and were not conducive to genotyping many SNPs rapidly. More recently, with the increased interest in SNPs as tools for mapping genes and for candidate gene association studies, techniques for high-throughput SNP genotyping have begun to be developed. As the underlying strategies for the newer high-throughput techniques and the older, more labor intensive techniques are both based fi rst on a reaction that discriminates which nucleotide is present at the polymorphic site and second on a technique that allows the identifi cation of the product of the reaction, we discuss in detail several of the older techniques that are found in much of the literature published thus far to illustrate the general concepts. A brief discussion of high-throughput techniques is included at the end of this section.

Generally when genotyping an SNP, the two possible nucleotides found at the site are known from sequencing, and a technique is used to distinguish one nucleotide from the other. When the polymorphic site is within a recognition site for a restriction enzyme, the ability of the restriction enzyme to cleave the PCR product can be used to determine which nucleotide is present at the polymorphic site (Figure 16 .1A). Whether the PCR product is cleaved is demonstrated by the size of the DNA as determined by electrophoresis.

Another way to determine whether a specifi c nucleotide is present at a polymorphic site is by performing allele-specifi c PCR (copies of DNA with different nucleotides at a specifi c polymorphic site are considered to be different alleles of the gene; Figure 16 .1B). Allelespecifi c primers that are identical except for the last nucleotide are used in the PCR reaction. Polymerase chain reactions generate new pieces of DNA by the addition of nucleotides to the 3′ end of the primer that has hybridized to the DNA of interest, which acts as a template. If there is no match at the 3′ end of the primer, the polymerase extends the primer at a 100-to 10,000-fold lower effi ciency, and no PCR product is detected. If the last nucleotide of the primer hybridizes to the specifi c allele it is designed to detect, a PCR product is formed if the individual has a copy of that allele. Presence or absence of the PCR product is determined by electrophoresis. To genotype an individual using the allele-specifi c PCR technique, two different PCR reactions are performed with one or the other allelespecifi c primer and a second primer common to both reactions.

Another technique that is often used to genotype SNPs is based on hybridization with allele-specifi c oligonucleotide (ASO) probes that are labeled so they can be detected (Figure 16 .1C). Such probes differ only by a single nucleotide (the polymorphic site, which is generally in the middle of the ASO). In the simplest of these types of assays, hybridization conditions are chosen such that each ASO hybridizes only to its specifi c allele. The presence of one mismatched nucleotide is enough to prevent annealing under the hybridization conditions used. The DNA sequence surrounding the polymorphic site determines whether conditions can be identifi ed in which the ASO probe hybridizes only to its matching allele and not to the other allele. If this is not possible, the less stable DNA duplex (that containing the mismatched nucleotide) can be distinguished from the perfect match by its melting temperature (Tm), which is an indicator of the stability of the duplex. The mismatched duplex is less stable and consequently has a lower Tm. This technique, however, is more complicated and time consuming.

In the past several years, new high-throughput techniques have been developed for SNP genotyping, some of which are beginning to be used in studies of critically ill patients [3, 4] . These techniques include some that are performed in solution and others that are solid-phase reactions performed on supports such as beads or microarray chips. Most of these techniques use hybridization, single base pair extension or "mini-sequencing," or allele-specifi c PCR to distinguish one allele from another. Some of the detection techniques used include fl uorescence, fl uorescence polarization, and mass spectrometry. The different techniques available and their advantages and disadvantages have been reviewed by others elsewhere [1, 2, [5] [6] [7] [8] . Which of these techniques will prove the most reliable and cost effective is not yet known. Certainly care will have to be used in applying these techniques, and appropriate controls will be required to illustrate reproducibility and reliability.

Individuals respond to infections and antimicrobial therapies in a highly variable fashion. Most patients will recover and do well, while a small but signifi cant portion will develop severe sepsis and The polymorphic site has either a T or a C. When the T is present, a restriction enzyme recognition site is formed that is cleaved in the presence of the restriction enzyme as determined by gel electrophoresis. If C is present at the site, the restriction enzyme does not cut. (B) Genotyping by allele-specific polymerase chain reaction (PCR). Reactions contain a common primer and an allele-specific primer ending with one of the nucleotides found at the polymorphic site. In this example, the allele-specific primer shown is for the T allele and only extension from the allele-specific primer, not the common primer. If the patient has the T allele, the last nucleotide will hybridize and extension will occur, allowing a productive PCR reaction. If the patient contains the C allele, the last nucleotide of the primer cannot hybridize and extension does not occur, resulting in no PCR product. With this technique two PCR reactions have to be performed with each patient sample. Each reaction contains a common primer and one of the two allele-specific primers. The presence of a PCR product is determined by gel electrophoresis. (C) Genotyping by allelespecific hybridization. Two allele-specific oligonucleotide (ASO) probes are made that are identical except for the polymorphic site. The probes are tagged for visualization as indicated by the stars. Only the allele-specific probe for the T allele is shown. The ASO will hybridize only to the DNA that contains a perfectly matched complementary sequence, in this case the T allele. Although only one reaction is shown (that containing the ASO with the T), two reactions containing the two different ASOs are performed for each patient sample. When unhybridized probe is washed away the hybridization can be visualized in a variety of ways.

may develop multiple organ system failure, refractory hypotension, and die. This variability in the susceptibility to and outcome from sepsis, which is considered to be the most common cause of death in children in the world, has been attributed to a number of factors. These include the virulence of the etiologic agent and the length of time between onset of symptoms and initiation of treatment. However, the genetic makeup of the host also appears to play an important role in the susceptibility to and the development of sepsis, as well as its severity and outcome. For example, familial studies in which there were deaths due to severe infections demonstrated a strong genetic infl uence [9] . The body's infl ammatory response to bacterial infection fi rst requires recognition of pathogen-associated bacterial products. The initial recognition and the resultant response require dozens of cellular proteins, many of which are polymorphic. Genetic variation within these polymorphic genes may infl uence the overall response to the infection. In this section we discuss the evidence that genetic variability in specifi c genes plays a role in development of sepsis and its outcome [for review, see 10].

Thus far, studies demonstrating associations between genetic polymorphisms in some of the genes coding for proteins involved in recognition and response to bacterial infection, and susceptibility to and outcome from sepsis, have implicated several genes involved with pathogen recognition as possibly being involved in the variability observed in individuals. Such genes include the toll-like receptor 4 (TLR4) gene, the mannose binding lectin (MBL) gene, and the Fcγ receptor (FcγR) genes (Table 16 .1).

Lipopolysaccharide (LPS), one of the major components of the cell wall of Gram-negative bacteria, binds to a cell surface receptor composed of at least three proteins: TLR4, CD14, and MD-2 [11] [12] [13] [14] [15] . A number of studies suggest that variations in the TLR4 gene can generate variability in susceptibility and/or response to infection. In mice, TLR4 is required for response to LPS [16] , and a single amino acid change can signifi cantly reduce response to LPS [14, 17] and enhance susceptibility to infection. In the human TLR4 gene, two SNPs have been identifi ed that result in the replacement of an aspartic acid at amino acid position 299 with glycine and a threonine at amino acid position 399 with an isoleucine. The Gly299Ile399 variant appears to be expressed at lower levels in human airway epithelia [18] , and a number of studies have demonstrated association of this variant with a reduced response to LPS as determined by examining airway reactivity or systemic cytokine response to inhaled LPS [18] [19] [20] . This variant is also associated with a diminished response to LPS in a transfected cell system using primary human epithelial cells [18] . An association of the TLR4 Gly299Ile399 variant with Gram-negative bacterial infections and septic shock [21, 22] and mortality in systemic infl ammatory response syndrome [23] has also been demonstrated in humans. However, the Gly-299Ile399 variant showed no association with susceptibility to, or severity of, meningococcal disease [24] , although other rare TLR4 mutations have been implicated in meningococcal susceptibility [25] . The lack of any association of the Gly299Ile399 variant with meningococcal disease may be explained by the observation that Neisseria meningitides is capable of eliciting an infl ammatory response via the TLR2 receptor in the absence of LPS [26, 27] .

Another component of the host immune system involved in recognition of bacterial invasion is the group of leukocyte Fcγ receptors (see Table 16 .1). These receptors bind to the constant region of IgG and are primarily responsible for the phagocytosis of immunoglobulin G (IgG)-coated bacteria and induction of the infl ammatory response [28, 29] . The human Fcγ receptors are grouped into three classes, which vary in their affi nity for the various IgG subclasses. The FcγRI class consists of the FcγRIa receptor; the FcγRII class consists of FcγRIIa, FcγRIIb, and FcγRIIc; and the FcγRIII class consists of FcγRIIIa and FcγRIIIb. Genetic polymorphisms affecting function have been described in three of the Fcγ receptors [29] . The FcγRIIIa has a polymorphism at amino acid 158 resulting in either a valine (V) or phenylalanine (F) at this position, which in turn affects its affi nity for IgG 1 , IgG 3 , and IgG 4 [30, 31] . The FcγRIIIb has a polymorphism that is a four amino acid substitution (allotypes FcγRIIIb-NA1 or -NA2), resulting in differences in glycosylation [32] . This substitution alters the opsonization effi ciency Variants B, C, D Variants associated with decreased levels and activity; associated with increased risk of infection TNF-α −308 G/A, others A associated with increased levels; associated with increased mortality in sepsis and meningococcal disease LT-α or TNF-β LT-α+250 G/A A associated with increased levels; associated with increased mortality in sepsis and bacteremia IL-1RA Variable 86-bp repeat A2 associated with increased levels of IL-1RA; variable results of association studies examining risk of sepsis and mortality IL-6 −174 G/C G associated with increased IL-6 levels in patients, but C associated with increased levels in monocytes from neonates; associated with sepsis in neonates but not adults IL-10 −1082 G/A, −819 C/T, GCC haplotype associated with −592 C/A increased levels; associated with sepsis but not mortality HSP70-2 +1267 G/A G associated with lower mRNA levels; A associated with septic shock in adults with CAP ACE I/D DD associated with increased serum and tissue levels; associated with more severe meningococcal disease PAI-1 4G/5G 4G associated with increased levels; associated with septic shock in meningococcal disease *The terms used for the various polymorphisms are the ones most commonly used in the literature and may refer to the nucleotide position, amino acid position, or name of the allele. This table is representative of polymorphisms examined in sepsis but does not include all such polymorphisms. Note: TLR, toll-like receptor; Ig, immunoglobulin; MBL, mannose binding lectin; TNF, tumor necrosis factor; LT, lymphotoxin; IL-1RA, interleukin-1 receptor antagonist (GCC haplotype of the IL-10 promoter is defined by three single-site polymorphisms at −1082, −819, and −592); HSP, heat shock protein; CAP, community-acquired pneumonia; ACE, angiotensin-converting enzyme; PAI, plasminogen activator inhibitor.

required for phagocytosis of IgG 1 -and IgG 3 -opsonized particles [33, 34] . Individuals homozygous for the FcγRIIIb-NA1 allotype appear to have more effi cient phagocytosis. The FcγRIIa gene has a polymorphic site at amino acid position 131 [35, 36] that results in either a histidine (FcγRIIa-H131) or an arginine (FcγRIIa-R131) at amino acid position 131. This amino acid is in the extracellular domain of the receptor, and the FcγRIIa-R131 allotype binds the Fc portion of IgG 2 with lower affi nity than the more common FcγRIIa-H131 allotype [36] . In vitro studies have demonstrated reduced phagocytosis of IgG 2 -opsonized particles in cells from individuals homozygous for FcγRIIa-R131 compared with cells from individuals homozygous for FcγRIIa-H131 [37, 38] . Immunoglobulin G 2 is the main antibody subtype directed against encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus infl uenzae type b, and N. meningitides and plays an important role in their phagocytosis [36, 39, 40] . Studies have examined the association between the presence of the FcγRIIa-R131 and/or the FcγRIIIb-NA2 polymorphisms in individuals and an increased susceptibility to infections, particularly meningococcal disease. Although the vast majority of reports have shown an association between infection and/or sepsis and the FcγRIIa and FcγRIIIb polymorphisms, there are two reports where no association was seen [41, 42] . However, in most studies higher frequencies of the FcγRIIa-R131/R131 or FcγRIIIb-Na2/Na2 genotypes have been found in patients with meningococcal disease [43] [44] [45] [46] [47] [48] , particularly in patients with severe meningococcal disease [45, 46] or fulminant meningococcal septic shock [43, 44] when compared with a healthy control population. An association between the FcγRIIa polymorphism and infection with other encapsulated bacteria has also been reported [49, 50] . Thus, genetic variation in the gene coding for at least two of the Fcγ receptors appears to infl uence the susceptibility to and outcome from infection with encapsulated bacteria. Mannose binding lectin is also involved with the opsonization [51] of bacteria and binds to bacterial surface oligosaccharides Nacetyl glucosamine and mannose [52] . The heterotrimeric MBL protein contains a carbohydrate binding domain and a helical tail domain that is important in polymerization of the three peptides [53] . Polymerization of the heterotrimer is crucial for the stability of MBL. Three genetic polymorphisms have been described in MBL in the amino acids at the positions 52, 54, and 57 (referred to as variants D, C, and B, respectively). These polymorphic sites result in amino acid changes that diminish the ability of the helical tails to polymerize, resulting in an increased degradation of MBL [51, 54, 55] and reduced serum levels of MBL [55] . Studies have demonstrated associations among these MBL genetic polymorphisms and increased susceptibility to infections [56] , hospitalizations because of infections in children [57] , number of acute respiratory infections in children [58] , increased risk for meningococcal infections [59] , susceptibility to infections in patients with systemic lupus erythematosus [60] , increased risk for recurrent respiratory infections [61] , and increased susceptibility to invasive pneumococcal disease even in individuals with at least one copy of the variant polymorphism [62] . Thus, as with the genetic polymorphisms in the genes coding for the FcγRIIa and FcγRIIIb receptors, there appears to be an association between the MBL genetic variants and susceptibility to bacterial infections.

Proinfl ammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and IL-6, are produced and secreted within minutes of a pathogenic stimulus and result in the secretion of many other cytokines and chemokines. This is balanced by the subsequent release of antiinfl ammatory cytokines such as IL-10 and a return to baseline of cytokines and chemokines [63, 64] . It is now generally accepted that an overexaggerated proinfl ammatory response resulting in an imbalance between the proinfl ammatory and antiinfl ammatory cytokines results in the clinical manifestation of severe sepsis and septic shock. The mechanism by which this imbalance occurs leading to exaggerated response is an area of intense research. Genetic variability within genes coding for the proinfl ammatory and antiinfl ammatory cytokines might infl uence this balance and could potentially infl uence the overall susceptibility to and outcome from the sepsis.

Tumor necrosis factor-α and the genetic polymorphisms within the regulatory regions of the gene coding for TNF-α are perhaps the most extensively studied of all sepsis-induced cytokines. We will discuss the genetic polymorphisms found in the TNF-α locus in more detail here and briefl y mention other polymorphisms and association studies. As a proinfl ammatory cytokine, TNF-α plays a key role in the pathogenesis of the acute infl ammatory response and is responsible for the activation of the infl ammatory response. Tumor necrosis factor-α is also responsible for the development of the harmful effects of the systemic infl ammatory response such as capillary leak, hypotension, acute respiratory distress syndrome (ARDS), and multiple organ system failure [65] [66] [67] [68] [69] . Several SNPs within the regulatory region of the gene coding for TNF-α have been identifi ed that impact TNF-α production [70] [71] [72] [73] [74] [75] [76] [77] . The most studied are the G to A transitions 308 and 238 base pairs upstream from the transcriptional start site for the TNF-α gene. In vitro studies have demonstrated that the rarer TNF-α-308A allele is associated with increased transcription [77] and increased secretion of TNF-α from LPS-stimulated macrophages [72] compared with the more common TNF-α-308G allele. In contrast, the more common TNF-α-238G allele is associated with higher TNF-α production in vitro compared with the rarer TNF-α-238A allele [78] . These polymorphisms lie near putative DNA binding sites for several transcription factors, and in vitro studies have demonstrated differential binding of nuclear proteins to DNA fragments containing either an A or a G at the TNF-α-308 position [79] .

Another polymorphism associated with higher levels of TNF-α is approximately 250 base pairs downstream from the transcriptional start site for the gene coding for lymphotoxin-α (LT-α, also known as TNF-β). This site (also referred to as the TNFB allele, LT-α+250, and TNF-β+252 site; for this chapter, LT-α+250 site will be used) is approximately 3.2 kb upstream from the TNF-α gene. Higher serum levels of TNF-α have been demonstrated in septic patients with the LT-α+250A allele [73] [74] [75] . Consequently, either this region acts as an enhancer for the TNF-α gene, or it is linked to a regulatory region further downstream. In any case, the data from studies of the TNF-α-308, TNF-α-238, and LT-α+250 alleles provide convincing evidence that genetic variation within regulatory regions of the gene coding for TNF-α infl uences the amount of TNF-α produced.

Most association studies have suggested that the TNF-α polymorphisms infl uence the clinical presentation and/or outcome in children with meningococcal infections [80] or bacteremia [73] and in adults with septic shock [70, 75, 81, 82] , or community-acquired pneumonia [83] . Specifi cally, the frequency of the TNF-α-308A allele is higher in adults who died with septic shock [82] and in children who died from meningococcal disease than in controls [80] . Even those children who were heterozygous at this position (TNF-α-308 G/A) were at increased risk for more fulminant meningococcal disease and death compared with those children who were homozygous for the wild-type genotype (TNF-α-308 G/G). At the LT-α+250 site, analysis of a cohort of adults with communityacquired pneumonia demonstrated that those with the A/A genotype were at greater risk for presenting with the clinical symptoms of sepsis [83] . Patients in postoperative and trauma intensive care units who developed sepsis and were homozygous for the LT-α+250 A allele have higher levels of TNF-α and a higher mortality rate [75, 84, 85] . Similarly, an association among the LT-α+250 A allele, higher serum levels of TNF-α, and higher mortality rate in bacteremic children has been observed [73] . Children who were heterozygous at this position (LT-α+250 GA) had an intermediate mortality rate. Thus, most evidence appears to support an association among certain genotypes in the regulatory region of the gene coding for TNF-α, levels of TNF-α production, and mortality rate of patients with sepsis.

Genetic polymorphisms in many other proinfl ammatory and antiinfl ammatory cytokines that infl uence the levels or function of the cytokines have also been examined to determine whether these genetic variations are associated with susceptibility to or outcome from sepsis (see Table 16 .1). These include IL-1α, IL-1β, IL-1 RA [86] [87] [88] , IL-6 [89] [90] [91] , IL-8 [92] [93] [94] [95] , and IL-10 [96] [97] [98] [99] , and the list continues to grow rapidly as more polymorphisms in cytokine genes are discovered. Several of the above-mentioned cytokines contain polymorphisms that appear to be associated with sepsis. The reader is referred to a recent review for more detail [10] .

Genetic polymorphisms within noncytokine genes have also been examined for the infl uence of genetic variations on critically ill patients. Heat shock proteins (HSPs) are a family of stress-inducible proteins expressed in response to heat as well as a number of other noxious stimuli, including endotoxin and other mediators of severe sepsis [100] . These proteins play an important role in cell survival during stress [101] and are involved in a number of important cellular functions, including the folding, assembly, and translocation of proteins across membranes [102, 103] . Polymorphisms within the genes coding for HSPs that infl uence HSP production [104] have been shown to be associated with more organ system failure in trauma patients [105] and the development of septic shock but not mortality in adults with community-acquired pneumonia [106] .

Angiotensin I-converting enzyme (ACE) is present in all tissues, particularly the pulmonary endothelium. Angiotensin I-converting enzyme is primarily responsible for converting angiotensin I to angiotensin II but is also involved in the metabolism of chemotactic peptides, suggesting that it may play a role in the infl ammatory response. Individuals have been shown to have variable plasma and tissue levels of ACE, and evidence suggests that these variable levels are caused in part by genetic factors [107] . Specifi cally, an insertion (I)/deletion (D) of a 287 base repair repeat sequence in the noncoding intron 16 of the gene coding for ACE [108, 109] is associated with variable plasma levels; individuals with the DD genotype have higher plasma and tissue levels of ACE than individuals who are heterozygous or are homozygous for the insertion sequence [110, 111] . Association studies have suggested that the D/D polymorphism is associated with more severe meningococcal disease in children as measured by a higher predicted risk of mortality, greater prevalence of inotropic support and mechanical ventilation, and longer intensive care unit stay [112] .

The pathogenesis of multiple organ system failure in sepsis is believed to involve in part endothelial dysfunction and intravascu-lar fi brin deposition [113] . Diminished activity of anticoagulants, or elevated levels of inhibitors of fi brinolysis, can lead to fi brin deposition and may contribute to multiple organ system failure. Plasminogen activator inhibitor 1 (PAI-1) is an inhibitor of fi brinolysis because of its ability to inhibit the potent fi brinolytic, plasminogen activator. High plasma concentrations of PAI-1 have been observed in sepsis [114] and severe meningococcal disease [115] , and high concentrations are correlated with worse outcome. A single nucleotide I/D polymorphism exists within the promoter region of the gene coding for PAI-1 that appears to infl uence the amount of PAI-1 production, with individuals homozygous for the 4G/4G genotype producing more PAI-1 than either individuals heterozygous (4G/5G) or homozygous for fi ve guanines (5G/5G) [116] . Children with the 4G/4G genotype who had meningococcal disease had higher plasma levels of PAI-1 [117] and an increased risk of death from sepsis than did children with either the 4G/5G or the 5G/5G genotype [117] [118] [119] . This polymorphism is not only associated with outcome from meningococcal disease but appears to be a marker for poor outcome after severe trauma [120] . Thus, there appears to be a strong association between the 4G/4G genotype in the PAI-1 gene, high plasma concentrations of PAI-1, and worse outcome in critical illness.

In summary, there are a number of polymorphisms within genes involved in recognition of bacterial pathogens and response to bacterial pathogens that appear to be associated with the development of sepsis and its outcome (see Table 16 .1). In a number of cases, changes in the level or the function of the gene's protein product has been documented.

Respiratory failure is one of the major reasons for admission to both adult ICUs and PICUs. The causes of respiratory failure in children are too numerous to list here but include pulmonary causes such as ARDS, asthma, and bronchopulmonary dysplasia; infectious causes such as pneumonia and bronchiolitis; and neurologic causes such as central hypoventilation and ingestions. Thus, the list of potential genetic polymorphisms that may infl uence respiratory failure is likely to be very diverse. We discuss two examples of genes that play a role in respiratory physiology and infl ammation for which data suggest that polymorphisms may infl uence the degree of respiratory failure and lung injury in critically ill patients.

Community-acquired pneumonia is a primary cause of respiratory failure in both children and adults. Although most individuals with community-acquired pneumonia have minimal lung injury, a small but signifi cant number develop respiratory failure and severe lung injury. The most severe form of lung injury is ARDS and results in high morbidity and mortality in both children and adults. This variability in the degree of lung injury in patients with community-acquired pneumonia raises the possibility that genetic variation infl uences the susceptibility to and outcome from lung injury.

Genes coding for proteins involved in normal lung physiology, such as pulmonary surfactant, are ideal candidate genes in which genetic variation might infl uence the degree of lung injury and respiratory failure. Indeed, it has been suggested that alterations in surfactant may play important roles in these processes [121, 122] . Surfactant contains four major proteins, A, B, C, and D, which exhibit a variety of functions, including a role in host defenses in the lung [123] [124] [125] [126] [127] [128] and the reduction of surface tension at the airliquid interface. The surfactant protein-A (SP-A) genes as well as SP-B, -C, and -D genes are polymorphic, and polymorphisms in these genes have been associated with lung disease [129] [130] [131] [132] . The polymorphisms in the SP-A genes (A1 and A2) and SP-B gene are the best characterized, and many reports have shown association of these genes with lung disease [130, 131, [133] [134] [135] [136] . We will discuss SP-B and how a common genetic polymorphism in the gene coding for SP-B may infl uence respiratory failure and lung injury in critically ill children.

Defi ciency in, or impaired activity of, SP-B is implicated in a variety of interstitial pulmonary diseases, including acute respiratory failure and death in newborns and mice [137] [138] [139] , increased sensitivity to hyperoxia [140] , human congenital proteinosis [141, 142] , respiratory distress syndrome in premature infants [143, 144] , and ARDS [130, 145, 146] . Indeed, in patients with ARDS, both a lower level of surfactant proteins in bronchoalveolar lavage fl uid [146, 147] and a diminished ability of surfactant to lower surface tension have been found [148] . In addition, calfactant, a natural lung surfactant containing high levels of SP-B, improved oxygenation and decreased mortality in children with acute lung injury [149] . Genetic variations in the regulatory or functional regions of the gene encoding for SP-B may, therefore, infl uence susceptibility to, and outcome from, severe lung injury and respiratory failure.

The gene coding for SP-B is located on chromosome 2 and consists of 11 exons, including a 3′-untranslated sequence [150] . Surfactant protein-B is synthesized as a 381-amino acid precursor protein that is proteolytically cleaved to the active 79-amino acid form. Several SNPs within intron 2, exon 4, and the 5′ and 3′ fl anking regions of the gene coding for SP-B have been identifi ed. A C/T nucleotide variation at position 1580 in exon 4 changes amino acid 131 from threonine to isoleucine [141] , altering a site for N-linked glycosylation [151, 152] . Glycosylation of this site may impact the processing and/or function of SP-B [152, 153] resulting in decreased functional SP-B. We have examined the genetic polymorphism in the SP-B+1580 site in adults with community-acquired pneumonia and demonstrated that a higher percentage of those individuals with the less common C/C genotype developed respiratory failure requiring mechanical ventilation and met the criteria for ARDS compared with those individuals with the T/C or T/T genotypes [154] . Whether or not this polymorphism is associated with more severe lung injury in children with community-acquired pneumonia is currently being investigated.

Another candidate gene in which polymorphisms might be associated with more severe lung injury is the gene coding for ACE. As mentioned earlier, ACE is present in the pulmonary endothelium and is responsible for converting angiotensin I to angiotensin II (ATII). In adults with ARDS, ACE concentrations in bronchoalveolar lavage fl uid are elevated [155] as are the transpulmonary gradient and circulating concentrations of ATII [156] . An association between the D allele, which is associated with higher plasma tissue levels of ACE as described earlier, and ARDS has been observed in adults [157] . A higher percentage of adults with ARDS had the D/D genotype than did adults who were at risk for the development of ARDS, including those who underwent coronary artery bypass graft surgery or were in the ICU for other reasons. Thus, the genetic variation in the ACE gene may be associated with more severe lung injury.

Children who have undergone cardiovascular surgery represent a signifi cant number of patients in pediatric and/or cardiovascular intensive care units. Whether genetic polymorphisms are associated with various complications in the post-operative period in this population is another area of intense research. One of the potential sources of many of the complications observed in the post-operative period may be the release of infl ammatory mediators, including TNF-α, IL-6, IL-8, and ATII [158] . Studies of adults and children undergoing cardiovascular surgery involving the use of cardiopulmonary bypass have demonstrated a release of proinfl ammatory and antiinfl ammatory cytokines after surgery [159] . Various stimuli have been suggested to initiate cytokine release after cardiopulmonary bypass, including exposure of blood to the foreign surface of the bypass machine, complement activation [160, 161] , ischemia-reperfusion injury [162] , and endotoxin released because of gastrointestinal tract hypoperfusion [163] . Whatever the inciting event, this infl ammatory cascade may result in postoperative complications such as cardiovascular instability, systemic infl ammatory response syndrome, and multiple organ dysfunction [164] [165] [166] . As discussed previously, genetic variation infl uences the levels of many of the proinfl ammatory and antiinfl ammatory cytokines. It is plausible, therefore, that the complications observed in patients after exposure to cardiopulmonary bypass may be, in part, infl uenced by genetic variation.

Few studies have examined the association between polymorphisms in genes involved in infl ammation and complications in children who have undergone cardiac surgery, and, therefore, we will discuss studies examining these associations in adults who have undergone coronary artery bypass graft (CABG) surgery. Mechanical ventilation greater than 24 hours after CABG is considered prolonged and is a well-known complication of CABG observed in adults. Approximately 6% of patients undergoing their fi rst CABG surgery and 11% of those undergoing repeated CABG surgery are unable to be tracheally extubated by 24 hours [167] . The etiologies for prolonged mechanical ventilation include both pulmonary-related (atelectasis, bronchospasm, congestive heart failure [CHF], ARDS, and acute lung injury) and nonpulmonary-related (cerebrovascular accident, cardiogenic shock, and excess postoperative bleeding) events. Understanding the underlying mechanisms resulting in prolonged mechanical ventilation might allow both identifi cation of those patients at increased risk and development of therapies and strategies specifi c for such patients.

The associations between genetic polymorphisms located in genes coding for TNF-α, LT-α, IL-10, IL-6, and ATII and various complications after cardiopulmonary bypass have been studied [168] [169] [170] [171] [172] . We have examined the association between some of these polymorphisms and prolonged mechanical ventilation in adults who have undergone CABG surgery [173] . Adults with the A/A "TNF-α hypersecretor" genotype at either the TNF-α-308 or the LT-α+250 sites demonstrated overall shorter times to extubation and lower risk of prolonged mechanical ventilation. This appears to be contrary to the idea that hypersecretion of proinfl ammatory mediators may be detrimental to patients in the postoperative period [174, 175] . Possible explanations for the apparent benefi cial effect of TNF-α are that TNF-α appears to protect the myocardium from hypoxic insults [176, 177] and that TNF-α stimulates protective HSPs [178] [179] [180] . Further studies are needed to better defi ne the role of proinfl ammatory mediators in prolonged mechanical ventilation in this population.

Another potential mediator that could play a role in postoperative complications is ATII. Animal studies have demonstrated that ATII plays a role in myocardial ischemia-reperfusion injury [181] and contributes to depression of myocardial function [182] . Elevation of ATII may contribute to various causes of prolonged mechanical ventilation discussed earlier; for instance, its role in ischemia-reperfusion injury may contribute to postoperative ARDS/acute lung injury, whereas cardiac effects may increase postoperative CHF. As mentioned previously, ACE is present in the pulmonary endothelium and converts ATI to ATII. Concentrations of ACE are elevated after CABG surgery [183] , and these elevated concentrations appear to be infl uenced in part by genetic polymorphisms. Other studies have demonstrated that adults with the D allele had higher mortality and restenosis rates after CABG surgery compared with patients with the I allele [184] . Also, as mentioned previously, the D allele appears to be associated with susceptibility to and prognosis of ARDS [157] , an important cause of prolonged mechanical ventilation in the postoperative period for adults who have undergone CABG surgery. The ACE D allele is also associated with prolonged mechanical ventilation in this population except for patients who had their CABG procedure off-pump [185] . This observation suggests that the off-pump approach for those patients with the D/D genotype who are at higher risk for prolonged mechanical ventilation may decrease the incidence of this complication.

The risk for prolonged mechanical ventilation in the CABG population (like many of the conditions treated in the ICU) may be infl uenced by multiple proteins and their genetic polymorphisms. Currently there are an increasing number of studies examining the association of genetic polymorphisms in multiple genes with certain clinical conditions. The associations of the I/D polymorphism in the ACE gene and the TNF-α-308 and LT-α+250 polymorphisms with the risk of prolonged mechanical ventilation in the CABG population have been analyzed. Individuals with the G/G haplotype at TNF-α-308 and LT-α+250 loci and the D/D polymorphism of the ACE gene had a signifi cantly higher adjusted hazards ratio than did individuals who did not have the G/G haplotype at TNF-α-308 and LT-α+250 loci and had the I/I polymorphism of the ACE gene [185] . Thus, data are beginning to suggest that some of the postoperative complications observed after cardiopulmonary bypass may be infl uenced by genetic variation in the host. In addition, the possible infl uences of genetic variation in receptors and/or components of the signal transduction pathways of the various inotropic agents, vasoconstrictors, and vasodilators used in the care of children who have undergone cardiovascular surgery are also beginning to be analyzed.

Thromboses in both arteries and veins are signifi cant problems in children in PICUs [186] [187] [188] [189] [190] [191] [192] . These children are exposed to multiple risk factors for thrombosis, including sepsis and central venous catheters, with reports of deep venous thrombosis in 7.5% to 50% of children with central venous catheters [193] [194] [195] [196] . A number of inherited defects in the coagulation and thrombolytic systems also predispose children to thrombosis [197] [198] [199] . These defects can result in hyperactive coagulation, hypoactive anticoagulation, or hypoactive fi brinolysis. Several genetic variations (Table 16. 2) have been identifi ed in genes coding for components of the coagulation system that infl uence the quantity or function of these proteins and have been shown to be signifi cant risk factors for thrombosis [198, 200] . These include variations in genes coding for factor V [201] , prothrombin [202] [203] [204] [205] , antithrombin [206] [207] [208] [209] [210] , protein C [211] [212] [213] [214] [215] , protein S [216] [217] [218] [219] [220] [221] , methylentetrahydrofolate reductase [222] , endothelial nitric oxide synthase [223] [224] [225] , α-fi brinogen [226] [227] [228] [229] , and factor XIII [228, [230] [231] [232] [233] [234] [235] . However, no researchers have reported the relative risks of these various genetic polymorphisms in the development of thrombosis in children in PICUs. The Arg506Gln polymorphism in the factor V gene (factor V Leiden) has been reported in 13%-45% of pediatric patients with thromboembolism [236] [237] [238] [239] , but this population may not necessarily refl ect the population of PICU patients who also have the other nonhereditary risk factors mentioned earlier. Because the development of thrombosis can be deterred with anticoagulants, knowledge of a child's genetic polymorphisms in the genes coding for components of the coagulation system might identify children who could benefi t most by anticoagulant therapies.

Another area of pediatric critical care in which genetic polymorphisms infl uence critical illness is pharmacology. Pharmacogenomics attempts to determine the genetic factors that affect the various aspects of drug action, including drug transport, binding to receptors and signal transduction, and metabolism. That genetics can infl uence some drug responses was fi rst suggested by associations between inheritance or ethnicity and abnormal drug responses and further defi ned through biochemistry and molecular genetics [for review, see refs. [240] [241] [242] [243] . While the list of genetic polymorphisms in genes coding for drug transporters, receptors, and enzymes involved in drug metabolism is growing rapidly [244] , there are very few examples of genetic polymorphisms that infl uence the action of drugs commonly used in PICUs. The best-described examples of genetic polymorphisms that infl uence drug response are those that are found in genes coding for enzymes involved in drug metabolism (Table 16 .3). One example is briefl y described here in order to demonstrate the clinical relevance of such genetic variations. Thiopurine S-methyltransferase (TPMT) is an enzyme primarily responsible for inactivation of the thiopurines mercaptopurine and azathiopurine used as immunosuppressants and chemotherapeutic drugs. Genetic polymorphisms in the gene coding for TPMT result in a nonfunctioning enzyme; thus, patients receiving mercaptopurine or azathiopurine who inherit the nonfunctional allele accumulate high concentrations of the active metabolites and are at risk for developing life-threatening hematopoietic toxicities [245] [246] [247] . Clinical diagnostic tests are available for detecting the SNPs in the TPMT gene that result in TPMT defi ciency, thereby allowing for the identifi cation of patients at high risk for thiopurine toxicities. Patients receiving mercaptopurine or azathiopurine who are genetically predisposed to be TPMT defi cient have been treated successfully for their oncologic diseases using approximately 5%-10% of the conventional dose of the thiopurines [245, 246] without the toxicities. This represents a good example of modifying drug therapies based on an individual's genetic makeup.

A second example of a genetic variability that may infl uence drug action involves the β 2 -adrenergic receptor (β 2 -AR). β 2 -Adrenergic receptor agonists are the most potent bronchodilators and continue to be the mainstay treatment for exacerbations of asthma [248] . β 2 -Agonists activate the β 2 -AR, resulting in coupling of the receptor-agonist complex to G s , which in turn activates adenylate cyclase and increases the intracellular production of cyclic AMP (cAMP), resulting in the dilation of the smooth muscle lining the small bronchiolar airways [249] . Substantial variation in β 2 -AR response between individuals has been observed [250] . Over the past several years many studies have examined the possibility that alterations in β 2 -AR function might be associated with asthma, severity of asthma, or asthma phenotypes.

A number of SNPs within the gene coding for the β 2 -AR have been identifi ed [251] . An SNP upstream of the coding region (−47 C/T) appears to be associated with the regulation of β 2 -AR expression in the cell [252, 253] . In addition, the two most common SNPs, glycine or arginine at position 16 (Gly16 or Arg16) and glutamic acid or glutamine at position 27 (Glu27 or Gln27), alter the amino acid sequence of the β 2 -AR, which in turn alters properties of the receptor [251] . More recently, Drysdale et al. [254] genotyped 13 SNPs in ∼80 individuals and identifi ed 12 different combinations of these individual SNPS in the β 2 -AR gene, meaning that there are 12 β 2 -AR haplotypes (and hence alleles). Only one haplotype has Glu at amino acid 27; this is also the only haplotype with C at the −47 polymorphic site [254] . The β 2 -AR variant with C at −47 has been shown to express lower levels of the receptor than variants with T at that site [252, 253] .

Studies have investigated the association of β 2 -AR SNPs with asthma, asthma phenotype, or treatment modalities. Such studies have been performed primarily with single SNPs in the adult Caucasian population. Although there is no strong evidence linking a specifi c β 2 -AR genotype to asthma, there are a number of studies linking specifi c genotypes to asthma phenotypes [255] [256] [257] [258] [259] [260] . In children there is an association between the homozygous Gly16 genotype and bronchodilator desensitization [261] , and we have recently reported an association of the Gln27Glu genotype with the need for aminophylline treatment in African-American children with status asthmaticus [262] . Aminophylline inhibits phosphodiesterase, the enzyme responsible for degradation of cAMP, and consequently the level of β 2 -AR-stimulated cAMP is greater and its degradation is delayed, prolonging the elevated cAMP levels in the cell. These results suggest that African-American children with this genotype may have diminished response to β 2 -agonist therapy and may respond more effectively to treatment with a phosphodiesterase inhibitor in addition to the β 2 -agonist therapy. One possible explanation for the association of the Gln27Glu genotype with aminophylline treatment is that these patients may have a lower β 2 -agonist-stimulated cAMP response than patients with the Gln27Gln genotype, and aminophylline addition may be required to increase cAMP to levels that are clinically effi cacious. Presumably the Glu27 variant is responsible, as the need for aminophylline treatment is seen only in patients who have this variant of the receptor. A lower cAMP response could be caused by lower expression of the Glu27 variant, which has been reported in in vitro studies [252, 253] , or by increased desensitization of the β 2 -AR Glu27 variant, which is still controversial as different studies have concluded that the Glu27 variant undergoes greater [263] or lesser [264] desensitization than the Gln27 variant.

Association studies attempting to examine the infl uence of genetic polymorphisms in specifi c diseases have several limitations that are important to keep in mind when reading the literature. A few of these limitations are briefl y discussed here, and the reader is referred to a more comprehensive review of these limitations [265] . First, it is important that the correct control population is used in the study. For example, in some sepsis studies the frequency of a polymorphism in the group of patients with sepsis is compared with the frequency of the polymorphism in a healthy control population. However, healthy individuals are not the appropriate control population, as they may not have been exposed to the same pathogens to which the patients with sepsis were exposed. A more appropriate control group for comparison would be a group of patients with a similar infection who did not develop sepsis.

A second limitation is that in many studies subjects within the study and control groups are from various ethnic groups. It is now well known that the frequency of many of these polymorphisms varies between ethnic groups and so comparisons should only be made within ethnic groups. Finally, the specifi c nucleotide variation being investigated may in fact not be directly involved but rather closely linked to the actual gene responsible for the effect.

In summary, there is little doubt that host genetic variation is responsible for some of the variable disease presentation, response to therapy, and fi nal outcome observed in critically ill children. Identifi cation of genetic polymorphisms that will ultimately be useful in identifying critically ill children at increased risk will allow for a more individualized approach to therapy. Carefully controlled studies examining candidate genes alone and in combination with other genes will be required to determine whether patient treatment can be tailored more specifi cally to an individual patient's genetic makeup.

Single nucleotide polymorphism seeking long term association with complex disease

Enabling large-scale pharmacogenetic studies by highthroughput mutation detection and genotyping technologies

Template-directed dye-terminator incorporation with fl uorescence polarization detection for analysis of single nucleotide polymorphisms implicated in sepsis

Template-directed dyeterminator incorporation with fl uorescence polarization detection for analysis of single nucleotide polymorphisms associated with cardiovascular and thromboembolic disease

Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput

Methods for genotyping single nucleotide polymorphisms

From gels to chips: "minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms

Accessing genetic variation: genotyping single nucleotide polymorphisms

Genetic and environmental infl uences on premature death in adult adoptees

Genetic polymorphisms in sepsis

Toll-like receptors in the induction of the innate immune response

Sepsis and evolution of the innate immune response

Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction

Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene

Regulation of receptor-dependent activation of the innate immune response

Cutting edge: toll-like receptor 4 (TLR4)-defi cient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product

Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4)

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans

Systemic responsiveness to lipopolysaccharide and polymorphisms in the toll-like receptor 4 gene in human beings

TLR4 gene variants modify endotoxin effects on asthma

Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections

Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock

Polymorphisms in toll-like receptor 4 and the systemic infl ammatory response syndrome

A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease

Assay of locus-specifi c genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility

Membrane-associated proteins of a lipopolysaccharide-defi cient mutant of Neisseria meningitidis activate the infl ammatory response through toll-like receptor 2

A lipopolysaccharide-defi cient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2

IgG receptor polymorphisms: risk factors for disease

FcγR polymorphisms: implications for function, disease susceptibility and immunotherapy

FcγRIIIa-158V/F polymorphism infl uences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype

A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phospho-inositol-linked Fcγ receptor III (CD16)

Fcγ receptor IIIb enhances Fcγ receptor IIa function in an oxidant-dependent and allele-sensitive manner

Fcγ receptor III on human neutrophils: allelic variants have functionally distinct capacities

Molecular basis for a polymorphism of human Fcγ receptor II (CD32)

A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding

Allelic polymorphisms of human Fcγ receptor IIA and Fcγ receptor IIIB. Independent mechanisms for differences in human phagocyte function

Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils

Quantitation of human IgG subclass antibodies to Haemophilus infl uenzae type b capsular polysaccharide. Results of an international collaborative study using enzyme immunoassay methodology

Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens

FcγRIIa and FcγRIIIb polymorphisms were not associated with meningococcal disease in Western Norway

Fcγ receptor allotypes in children with bacterial meningitis. A preliminary study

Fcγ receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children

Associations between Fcγ receptor IIA polymorphisms and the risk and prognosis of meningococcal disease

Meningococcal disease and polymorphism of FcγRIIa (CD32) in late complement component-defi cient individuals

Association of human Fcγ RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease

Relevance of Fcγ receptor and interleukin-10 polymorphisms for meningococcal disease

Polymorphism of IgG Fc receptors in meningococcal disease

Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia

Fcγ receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections

Mannose-binding lectin (MBL) in health and disease

The human mannose-binding protein functions as an opsonin

The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10

High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene

Molecular basis of opsonic defect in immunodefi cient children

Mannose binding protein gene mutations associated with unusual and severe infections in adults

Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series

Acute respiratory tract infections and mannose-binding lectin insuffi ciency during early childhood

Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group

Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus

Mannose-binding lectin gene polymorphism is a modulating factor in repeated respiratory infections

MBL genotype and risk of invasive pneumococcal disease: a case-control study

Points of control in infl ammation

The immunopathogenesis of sepsis

Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study

Interferon-γ and tumor necrosis factor-α suppress both early and late stages of hematopoiesis and induce programmed cell death

Shock and tissue injury induced by recombinant human cachectin

Progress of fi brinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fi brin(ogen) degradation products

Tumor necrosis factor's effects on lung mechanics, gas exchange, and airway reactivity in sheep

Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-α levels and mortality from septic shock

Polymorphism of the 5'-fl anking region of the human tumor necrosis factor (TNF)-α gene in Japanese

Tumour necrosis factor (TNF) gene polymorphism infl uences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans

Association between the A/A genotype at the lymphotoxin-α+250 site and increased mortality in children with positive blood cultures

Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus

A genomic polymorphism within the tumor necrosis factor locus infl uences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis

Single base polymorphism in the human tumour necrosis factor α (TNF α) gene detectable by NcoI restriction of PCR product

Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation

TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients

The -308 tumor necrosis factor-α promoter polymorphism effects transcription

Variation in the tumor necrosis factor-α gene promoter region may be associated with death from meningococcal disease

Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients

Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study

Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations

Relation of a TNF gene polymorphism to severe sepsis in trauma patients

−308 Tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter

Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis

Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis

Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist infl uence the severity of meningococcal disease

Is interleukin-6 −174 genotype associated with the development of septicemia in preterm infants?

Effect of the interleukin-6 promoter polymorphism (−174 G/C) on the incidence and outcome of sepsis

The association of interleukin 6 haplotype clades with mortality in critically ill adults

Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus

Haplotype mapping of the bronchiolitis susceptibility locus near IL8

Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility

Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families

Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis

Association of IL-10 polymorphism with severity of illness in community acquired pneumonia

Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism

Infl uence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients

Induction of heat shock gene expression in colonic epithelial cells after incubation with Escherichia coli or endotoxin

Heat shock, stress proteins, chaperones, and proteotoxicity

Molecular chaperone functions of heat-shock proteins

The function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins

The septic shock associated HSPA1B1267 polymorphism infl uences production of HSPA1A and HSPA1B

Heat shock protein 70 genotypes HSPA1B and HSPA1L infl uence cytokine concentrations and interfere with outcome after major injury

Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia

Familial resemblance of plasma angiotensinconverting enzyme level: the Nancy Study

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1)

Alhenc-Gelas F. Angiotensin Iconverting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes

Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels

Severity of meningococcal disease in children and the angiotensinconverting enzyme insertion/deletion polymorphism

Vascular bed-specifi c hemostasis: role of endothelium in sepsis pathogenesis

Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor α in patients with sepsis

Plasminogen activator inhibitor 1 and 2, α-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease

Allele-specifi c increase in basal transcription of the plasminogenactivator inhibitor 1 gene is associated with myocardial infarction

4G/5G promoter polymorphism in the plasminogenactivator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group

Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children

4G/5G promoter polymorphism in the plasminogen-activatorinhibitor-1 gene in children with systemic meningococcaemia

Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients

Surfactant and the adult respiratory distress syndrome

Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects

Pulmonary surfactant proteins A and D recognize lipid ligands on Mycoplasma pneumoniae and markedly augment the innate immune response to the organism

Human SP-A: then and now

Surfactant protein-A-defi cient mice are susceptible to Pseudomonas aeruginosa infection

Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways

Immunomodulatory functions of surfactant

Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability

Surfactant protein C gene variation in the Finnish population-association with perinatal respiratory disease

Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS

Surfactant gene polymorphisms and interstitial lung diseases

Immunoregulatory functions of surfactant proteins

Surfactant protein A and B genetic variants and respiratory distress syndrome: allele interactions

Surfactant protein (SP) B associations and interactions with SP-A in white and black subjects with respiratory distress syndrome

Family-based transmission disequilibrium test (TDT) and casecontrol association studies reveal surfactant protein A (SP-A) susceptibility alleles for respiratory distress syndrome (RDS) and possible race differences

Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants

Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice

Surfactant proteins: molecular genetics of neonatal pulmonary diseases

Human surfactant protein B: structure, function, regulation, and genetic disease

Surfactant protein-B-defi cient mice are susceptible to hyperoxic lung injury

An SP-B gene mutation responsible for SP-B defi ciency in fatal congenital alveolar proteinosis: evidence for a mutation hotspot in exon 4

A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds

Surfactant protein B polymorphism and respiratory distress syndrome in premature twins

Ontogeny of surfactant proteins A and B in human amniotic fl uid as indices of fetal lung maturity

Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS

Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome

Surfactant protein A (SP-A) is decreased in acute parenchymal lung injury associated with polytrauma

The adult respiratory distress syndrome: pathophysiological concepts related to the pulmonary surfactant system

Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial

Structure and organization of the gene encoding human pulmonary surfactant proteolipid SP-B

Isolation of a cDNA clone encoding a high molecular weight precursor to a 6-kDa pulmonary surfactant-associated protein

Differences in N-linked glycosylation between human surfactant protein-B variants of the C or T allele at the single-nucleotide polymorphism at position 1580: implications for disease

Role of individual N-linked glycosylation sites in the function and intracellular transport of the human α folate receptor

Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with communityacquired pneumonia

Angiotensin converting enzyme in bronchoalveolar lavage in ARDS

Inhaled nitric oxide does not change transpulmonary angiotensin II formation in patients with acute respiratory distress syndrome

Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome

Tumour necrosis factor as predictor for pulmonary dysfunction after cardiac surgery

Infl ammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies

Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins

Pacifi co AD. Complement and the damaging effects of cardiopulmonary bypass

Myocardial and microvascular injury following coronary surgery and its attenuation by mode of reperfusion

Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass

Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic infl ammatory response/multiple organ dysfunction syndromes

Systemic infl ammatory response syndrome after cardiac operations

Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor

Causes of prolonged mechanical ventilation after coronary artery bypass surgery

Genotype and interleukin-10 responses after cardiopulmonary bypass

The −174G/C interleukin-6 polymorphism infl uences postoperative interleukin-6 levels and postoperative atrial fi brillation. Is atrial fi brillation an infl ammatory complication?

Genetic polymorphisms of apolipoprotein E4 and tumor necrosis factor β as predisposing factors for increased infl ammatory cytokines after cardiopulmonary bypass

A tumor necrosis factor gene polymorphism infl uences the infl ammatory response after cardiac operation

Tumor necrosis factor gene polymorphism is associated with enhanced systemic infl ammatory response and increased cardiopulmonary morbidity after cardiac surgery

Association of tumor necrosis factor gene polymorphisms and prolonged mechanical ventilation after coronary artery bypass surgery

Aprotinin and methylprednisolone equally blunt cardiopulmonary bypassinduced infl ammation in humans

Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass

Tumor necrosis factor-α confers resistance to hypoxic injury in the adult mammalian cardiac myocyte

Cytoprotective mechanisms in cultured cardiomyocytes

Heat shock proteins and protection against myocardial ischemia

Heat shock protein suppresses the senescent lung cytokine response to acute endotoxemia

Heat shock response decreases endotoxin-induced acute lung injury in rats

Myocardial angiotensin II receptor expression and ischemia-reperfusion injury

Effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury: an overview

Changes in serum angiotensin-converting enzyme during cardiopulmonary bypass in humans

Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery

Clinical relevance of angiotensin-converting enzyme gene polymorphisms to predict risk of mechanical ventilation after coronary artery bypass graft surgery

Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a prospective study

Complications of central venous catheterization in critically ill children

Prevalence of deep venous thrombosis in the lower extremities of children in the intensive care unit

Venous catheter thrombus formation and pulmonary embolism in children

Venous thromboembolic disease in the pediatric intensive care unit

Femoral central venous catheter-associated deep venous thrombosis in children with diabetic ketoacidosis

Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications

Venous thromboembolic complications in children

Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding

A prospective study of femoral catheter-related thrombosis in children

Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands

Blood coagulation

Inherited thrombophilia: pathogenesis, clinical syndromes, and management

Genetics of thrombophilia: impact on atherogenesis

Mutation in blood coagulation factor V associated with resistance to activated protein C

The prothrombin 20210 G to A variation and thrombosis

Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels

Prothrombin A19911G and G20210A polymorphisms' role in thrombosis

A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis

Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate

Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys

A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin pescara, ARG393 to pro, caused by a CGT to CCT mutation

Antithrombin III mutation database: fi rst update. For the Thrombin and its Inhibitors Subcommittee of the Scientifi c and Standardization Committee of the International Society on Thrombosis and Haemostasis

Antithrombin III: summary of fi rst database update

Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk

Two mutations in the promoter region of the human protein C gene both cause type I protein C defi ciency by disruption of two HNF-3 binding sites

Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk

Genetic risk factors for venous thrombosis

Protein C defi ciency: a database of mutations

The Ser 460 to Pro substitution of the protein S α (PROS1) gene is a frequent mutation associated with free protein S (type IIa) defi ciency

The Ser460Pro mutation in recombinant protein S Heerlen does not affect its APCcofactor and APC-independent anticoagulant activities

The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation

Three novel mutations in fi ve unrelated subjects with hereditary protein S defi ciency type I

Identifi cation of eight point mutations in protein S defi ciency type I-analysis of 15 pedigrees

Identifi cation of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S defi ciency using a scanning method for the analysis of the protein S active gene

The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients

The 894 G > T variant of endothelial nitric oxide synthase (eNOS) increases the risk of recurrent venous thrombosis through interaction with elevated homocysteine levels

Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement

Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction

The molecular physiology and pathology of fi brin structure/function

Functional analysis of the fi brinogen α Thr312Ala polymorphism: effects on fi brin structure and function

α-Fibrinogen Thr312Ala polymorphism and venous thromboembolism

Analysis of prothrombotic mutations and polymorphisms in children who developed thrombosis in the perioperative period of congenital cardiac surgery

The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fi brin structure

Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia

Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A

The FXIII Val 34 Leu mutation and the risk of venous thrombosis

Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis

Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis

Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease

Disorders of hemostasis in childhood: risk factors for venous thromboembolism

Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism

Paediatric thrombo-embolism: the infl uence of non-genetic factors and the role of activated protein C resistance and protein C defi ciency

Pharmacogenomics: translating functional genomics into rational therapeutics

Pharmacogenetic perspectives gained from twin and family studies

Twenty years of biochemistry of human P450s: purifi cation, expression, mechanism, and relevance to drugs

Molecular mechanisms of genetic polymorphisms of drug metabolism

Moving towards individualized medicine with pharmacogenomics

Preponderance of thiopurine S-methyltransferase defi ciency and heterozygosity among patients intolerant to mercaptopurine or azathioprine

Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-defi cient child with acute lymphocytic leukemia

Inheritance and Drug Response

Recent advances in asthma

β-Adrenergic bronchodilators

Heterogeneity of therapeutic responses in asthma

Pharmacology and physiology of human adrenergic receptor polymorphisms

Polymorphisms of the 5' leader cistron of the human β2-adrenergic receptor regular receptor expression

Identifi cation of novel polymorphisms within the promoter region of the human β2-adrenergic receptor

Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

Association of β2-adrenergic receptor polymorphisms with severe asthma

The effect of polymorphisms of the β2-adrenergic receptor on the response to regular use of albuterol in asthma

Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects

Association between β2-adrenoreceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics

Asthma exacerbations during long term β agonist use: infl uence of β2 adrenoceptor polymorphism

Human lung cell β2-adrenergic receptors desensitize in response to in vivo administered β-agonist

Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing

Dahmer MK. β2-Adrenergic receptor polymorphisms in African American children with status asthmaticus

Polymorphism of the β2-adrenergic receptor gene and desensitization in human airway smooth muscle

Infl uence of β2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle

Assessing the quality of case-control association studies on the genetic basis of sepsis